Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341909 | 0.93 | OPRM1 (0.63) | HTR2AOPRM1POLBCCR5CTSD | |
| SCHEMBL339807 | 0.92 | HTR2A (0.61) | HTR2AOPRM1POLBCCR5UBE2M | |
| SCHEMBL342265 | 0.91 | OPRM1 (0.61) | HTR2AOPRM1POLBCCR5UBE2M | |
| SCHEMBL341027 | 0.90 | HTR2A (0.59) | HTR2AOPRM1POLBCCR5UBE2M | |
| SCHEMBL340406 | 0.90 | HTR2A (0.61) | HTR2AOPRM1POLBCCR5CTSD | |
| SCHEMBL342052 | 0.90 | OPRM1 (0.59) | HTR2AOPRM1POLBCCR5UBE2M | |
| SCHEMBL341145 | 0.90 | HTR2A (0.76) | HTR2AOPRM1POLB | |
| SCHEMBL341008 | 0.90 | OPRM1 (0.60) | HTR2AOPRM1POLBCCR5UBE2M | |
| SCHEMBL340934 | 0.89 | HTR2A (0.58) | HTR2AOPRM1POLBCCR5CTSD | |
| SCHEMBL340309 | 0.89 | OPRM1 (0.59) | HTR2AOPRM1POLBCCR5UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-4664564-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| JP-2003531829-A | — | — | 2003-10-28 | — | — | JP | claimed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | claimed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | HTR2A 10/4885OPRM1 210/4885POLB 1157/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | HTR2A 1/4885OPRM1 73/4885POLB 1504/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | HTR2A 1/4885OPRM1 193/4885POLB 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.